NCT00002798 - Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Biotech Hunter

Enrollment

880

Participants

Timeline

Start Date

August 31, 1996

Primary Completion Date

September 30, 2006

Conditions

Childhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic SyndromesChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRefractory Anemia With Ringed SideroblastsSecondary Myelodysplastic SyndromesUntreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions

DRUG

asparaginase

DRUG

daunorubicin hydrochloride

DRUG

fludarabine phosphate

DRUG

therapeutic hydrocortisone

PROCEDURE

allogeneic bone marrow transplantation

RADIATION

3-dimensional conformal radiation therapy

BIOLOGICAL

filgrastim

Given SC

DRUG

cytarabine

Given IV or IT

DRUG

idarubicin

Given IV

DRUG

dexamethasone

Given PO

DRUG

thioguanine

Given PO

DRUG

etoposide

Given IV

DRUG

methotrexate

Given IT

DRUG

cyclophosphamide

Given IV

BIOLOGICAL

aldesleukin

DRUG

busulfan

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH